Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Protein misfolding, aggregation and mechanism of amyloid cytotoxicity: An overview and therapeutic strategies to inhibit aggregation.

Zaman M, Khan AN, Wahiduzzaman, Zakariya SM, Khan RH.

Int J Biol Macromol. 2019 May 22;134:1022-1037. doi: 10.1016/j.ijbiomac.2019.05.109. [Epub ahead of print] Review.

PMID:
31128177
2.

Molecular chaperones biochemistry and role in neurodegenerative diseases.

Chaari A.

Int J Biol Macromol. 2019 Jun 15;131:396-411. doi: 10.1016/j.ijbiomac.2019.02.148. Epub 2019 Mar 7. Review.

PMID:
30853582
3.

[Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases].

Nagai Y.

Rinsho Shinkeigaku. 2009 Nov;49(11):913-6. Review. Japanese.

PMID:
20030247
4.

A review on protein misfolding, aggregation and strategies to prevent related ailments.

Shamsi TN, Athar T, Parveen R, Fatima S.

Int J Biol Macromol. 2017 Dec;105(Pt 1):993-1000. doi: 10.1016/j.ijbiomac.2017.07.116. Epub 2017 Jul 23. Review.

PMID:
28743576
6.

Phthalocyanines as Molecular Scaffolds to Block Disease-Associated Protein Aggregation.

Valiente-Gabioud AA, Miotto MC, Chesta ME, Lombardo V, Binolfi A, Fernández CO.

Acc Chem Res. 2016 May 17;49(5):801-8. doi: 10.1021/acs.accounts.5b00507. Epub 2016 May 2. Review.

PMID:
27136297
7.

Protein aggregation and ER stress.

Ogen-Shtern N, Ben David T, Lederkremer GZ.

Brain Res. 2016 Oct 1;1648(Pt B):658-666. doi: 10.1016/j.brainres.2016.03.044. Epub 2016 Mar 30. Review.

PMID:
27037184
8.

Unraveling the mysteries of protein folding and misfolding.

Ecroyd H, Carver JA.

IUBMB Life. 2008 Dec;60(12):769-74. doi: 10.1002/iub.117. Review.

9.

Structure and intermolecular dynamics of aggregates populated during amyloid fibril formation studied by hydrogen/deuterium exchange.

Carulla N, Zhou M, Giralt E, Robinson CV, Dobson CM.

Acc Chem Res. 2010 Aug 17;43(8):1072-9. doi: 10.1021/ar9002784.

PMID:
20557067
10.

Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.

Kvam E, Nannenga BL, Wang MS, Jia Z, Sierks MR, Messer A.

PLoS One. 2009 May 28;4(5):e5727. doi: 10.1371/journal.pone.0005727.

11.

Chemical chaperone and inhibitor discovery: potential treatments for protein conformational diseases.

Zhao JH, Liu HL, Lin HY, Huang CH, Fang HW, Chen SS, Ho Y, Tsai WB, Chen WY.

Perspect Medicin Chem. 2007 Dec 11;1:39-48.

12.

Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.

Meredith SC.

Ann N Y Acad Sci. 2005 Dec;1066:181-221. Review.

PMID:
16533927
13.

Protein misfolding in the late-onset neurodegenerative diseases: common themes and the unique case of amyotrophic lateral sclerosis.

Mulligan VK, Chakrabartty A.

Proteins. 2013 Aug;81(8):1285-303. doi: 10.1002/prot.24285. Epub 2013 Jul 2. Review.

PMID:
23508986
14.

Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine Diseases.

Takeuchi T, Nagai Y.

Brain Sci. 2017 Oct 11;7(10). pii: E128. doi: 10.3390/brainsci7100128. Review.

15.

Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases.

Popiel HA, Takeuchi T, Burke JR, Strittmatter WJ, Toda T, Wada K, Nagai Y.

Neurotherapeutics. 2013 Jul;10(3):440-6. doi: 10.1007/s13311-013-0184-7. Review.

16.

Polyglutamine induced misfolding of huntingtin exon1 is modulated by the flanking sequences.

Lakhani VV, Ding F, Dokholyan NV.

PLoS Comput Biol. 2010 Apr 29;6(4):e1000772. doi: 10.1371/journal.pcbi.1000772.

17.

The contribution of biophysical and structural studies of protein self-assembly to the design of therapeutic strategies for amyloid diseases.

Cremades N, Dobson CM.

Neurobiol Dis. 2018 Jan;109(Pt B):178-190. doi: 10.1016/j.nbd.2017.07.009. Epub 2017 Jul 12. Review.

18.

Antibodies and protein misfolding: From structural research tools to therapeutic strategies.

De Genst E, Messer A, Dobson CM.

Biochim Biophys Acta. 2014 Nov;1844(11):1907-1919. doi: 10.1016/j.bbapap.2014.08.016. Epub 2014 Sep 4. Review.

19.

Inhibition of protein misfolding and aggregation by natural phenolic compounds.

Dhouafli Z, Cuanalo-Contreras K, Hayouni EA, Mays CE, Soto C, Moreno-Gonzalez I.

Cell Mol Life Sci. 2018 Oct;75(19):3521-3538. doi: 10.1007/s00018-018-2872-2. Epub 2018 Jul 20. Review.

PMID:
30030591
20.

[Can prion-like propagation occur in neurodegenerative diseases?: in view of transmissible systemic amyloidosis].

Yoshida K, Higuchi K, Ikeda S.

Brain Nerve. 2012 Jun;64(6):665-74. Review. Japanese.

PMID:
22647474

Supplemental Content

Support Center